Hostname: page-component-78c5997874-ndw9j Total loading time: 0 Render date: 2024-11-05T15:02:21.594Z Has data issue: false hasContentIssue false

The role of the gut microbiota in mood and behaviour. Whether psychobiotics can become an alternative in therapy in psychiatry?

Published online by Cambridge University Press:  23 March 2020

S. Van Hemert
Affiliation:
Winclove Probiotics, Hulstweg 11, 1032 LBAmsterdam, Netherlands
W. Marlicz
Affiliation:
Pomeranian Medical University, Department of Gastroenterology, Szczecin, Poland
P. Szachta*
Affiliation:
Vitaimmun Medical Center, Research Department, Szczecin, Poland
E. Pekelharing
Affiliation:
Winclove Probiotics, Hulstweg 11, 1032 LBAmsterdam, Netherlands
G. Ormel
Affiliation:
Winclove Probiotics, Hulstweg 11, 1032 LBAmsterdam, Netherlands
I. Łoniewski
Affiliation:
Sanprobi, Sp. Z o.o. Sp. K., Szczecin, Poland
L. Ostrowska
Affiliation:
Medical University, Department of Dietetics and Clinical Nutrition, Bialystok, Poland
J. Samochowiec
Affiliation:
Pomeranian Medical University, Department of Psychiatry, Szczecin, Poland
*
* Corresponding author.

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

Novel research concepts based on therapies aiming to modulate intestinal microbiota are emerging. The evidence is mounting that gut-brain axis plays an important role in the development of mood and depressive disorders [1]. The similarities between blood brain barrier (BBB) and gut vascular barrier (GVB) and their role in chronic diseases have been recently unraveled [2]. Especially convincing data come from animal models, where administration of probiotics and antibiotics in germ and pathogen free mice showed beneficial role in the regulation of behavior, cognition, pain, anxiety and mood.

Aims and results

Based on available data as well as on studies looking at the effect of multispecies probiotics (Ecologic® Barrier containing B.bifidumW23, B.lactisW52, L.acidophilusW37, L.brevisW63, L.caseiW56, L.salivariusW24, L.lactisW19, L.lactisW58) on cognitive reactivity to sad mood in healthy volunteers [3] we designed the human trial aiming to compare microbiome alterations and response to therapy in patients with depression and schizophrenia. Moreover, in vitro and in vivo data support the notion that multispecies probiotics are capable of improving gut barrier function [4] and may alleviate disorders affecting mood and depressive-like behavior. We postulate that therapies modulating the microbiome-gut-brain axis warrant further investigations.

Conclusion

Multispecies probiotics have the potential to influence the gut-brain axis and alleviate mental disorders. Ongoing clinical study in patients with depression and schizophrenia will help to further unravel the role of gut-brain axis in the treatment of patients with psychiatric disturbances.

Disclosure of interest

The authors have not supplied their declaration of competing interest.

Type
S26
Copyright
Copyright © European Psychiatric Association 2016

References

Smith, P.A. Brain meet gut. Nature 2015; 526: 312314CrossRefGoogle Scholar
Spadoni, I. Zagato, E. Bertocchi, A., et al.A gut vascular barrier controls the systemic dissemination of bacteria. Science 2015; 350(6262): 830834CrossRefGoogle ScholarPubMed
Steenbergen, L. Sellaro, R. van Hemert, S., et al. A randomized controlled trial to test the effect of multispecies probiotics on cognitive reactivity to sad mood. Brain Behav Immun 2015CrossRefGoogle Scholar
Van Hemert, S. Ormel, G. Influence of the multispecies probiotic Ecologic® barrier on parameters of intestinal barrier function. Food Nutr Sci 2014; 5: 17391745Google Scholar
Submit a response

Comments

No Comments have been published for this article.